Development of docetaxel in advanced non-small-cell lung cancer

Lung Cancer

Volumn 46, Issue SUPPL. 2, 2004, Pages

  Belani, Chandra P ^a   Eckardt, John ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Center for Cancer Care and Research   (United States)

Author keywords

Docetaxel; Non small cell lung cancer; Taxane

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BETA TUBULIN; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; OPIATE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINBLASTINE; VINDESINE;

ALOPECIA; ANEMIA; ARTICLE; BINDING AFFINITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; LEUKOPENIA; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; METASTASIS; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN DISEASE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; PACLITAXEL; TAXOIDS; VINBLASTINE;

EID: 13244296961     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(04)80036-9     Document Type: Article

References (37)

1. Cancer Facts & Figures 2003 2003 American Cancer Society Atlanta, GA
2. SEER cancer survival statistics: 5-year survival rates for non-small cell lung and bronchus cancer 2003 National Cancer Institute Bethesda, MD
3. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer Anon. J Clin Oncol 15 1997 2996 3018
4. Central European Cooperative Oncology Group (CECOG) Advisory Committee on Collaboration with Industry in Medical Education of the European School of Oncology (ESO) Vienna Medical Association Consensus on medical treatment of nonsmall cell lung cancer Lung Cancer 38 2002 S3 S7
5. Socinski M.A., Morris D.E., Masters G.A., and Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer Chest 123 2003 2265 2435
6. Davies A., Lara P.N., Mack P.C., and Gandara D.R. Docetaxel in nonsmall cell lung cancer: a review Expert Opin Pharmacother 4 1993 553 565
7. Shepherd F.A., Dancey J., and Ramlau R. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated withplatinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
8. Gandara D.R., Vokes E., and Green M. Activity of docetaxel in platinum-treated non-small cell lung cancer: results of a phase II multicenter trial J Clin Oncol 18 2000 131 135
9. Fossella F.V., DeVore R., and Kerr R.N. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens J Clin Oncol 18 2000 2354 2362
10. Roszkowski K., Pluzanska A., and Krzakowski M A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients withmetastatic or nonresectable localized non-small cell lung cancer (NSCLC) Lung Cancer 27 2000 145 157
11. Fossella F., Pereira J.R., and von Pawel J. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group J Clin Oncol 21 2003 3016 3024
12. Schiller J.H., Harrington D., and Belani C.P. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
13. Gandara D.R., Chansky K., and Albain K.S. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study 59504 J Clin Oncol 21 2003 2004 2010
14. Mattson K.V., Abratt R.P., ten Veld G., and Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III nonsmall-cell lung cancer: a multinational randomised phase III study Ann Oncol 14 2003 116 122
15. Dancey J., Shepherd F.A., Gralla R.J., and Kim Y.S. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated withplatinum-based chemotherapy: results of a prospective, randomized phase III trial Lung Cancer 43 2004 183 194
16. Abstract 7036 Schuette W., Nagel S., and Serke M. Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: results of a randomized phaseIII study Proc Soc Am Oncol 23 2004 622
17. Abstract 7057 Lilenbaum R., Rubin M., and Samuel J. A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC) Proc Soc Am Oncol 23 2004 627
18. Kubota K., Watanabe K., and Kunitoh H. Phase III randomized trial of docetaxel-cisplatin versus vindesine-cisplatin with stage IV non-small cell lung cancer J Clin Oncol 22 2004 254 261
19. Georgoulias V., Pallis A.G., and Kourousis C. Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study Clin Lung Cancer 4 5 2003 288 293
20. Abstract 2505 Groen H., Schramel F.M., and Van der Hoeven J.J.M. Docetaxel and carboplatin once every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer (NSCLC). An interim analysis of amulticenter phase III trial Proc Am Soc Clin Oncol 22 2003 623
21. Abstract 1347 Huang C.H., Langer C.J., and Minniti C. Phase III toxicity trial of carboplatin (Cb) plus either docetaxel (D) or paclitaxel (P) in advanced non-small cell lung cancer (NSCLC): preliminary findings of OPN-001 Proc Am Soc Clin Oncol 21 2002 337a
22. Abstract 7066 Lorigan P., Booton R., and Ashcroft L. Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) -- final results of aBritish Thoracic Oncology Group (BTOG) trial Proc Soc Am Oncol 23 2004 629
23. Douillard J.-Y., Eckardt J., and Scagliotti G.V. Challenging the platinum combinations in the chemotherapy of NSCLC Lung Cancer 38 2002 S21 S28
24. Abstract 2846 Collins C.S., Delgadillo F., and Tellez E. Gemcitabine plus docetaxel in advanced non small cell lung cancer, phase II study Proc Am Soc Clin Oncol 22 2003 708
25. Abstract 2727 Yoshimura N., Kudoh S., and Matsui K. A phase I/II study of gemcitabine (G) combined with docetaxel (D) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2003 678
26. Abstract 2785 Tucker R.W., Miller A., Patton S., and Melin S. Phase II trial of weekly docetaxel and gemcitabine for metastatic non-small lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2003 692
27. Abstract 1276 Patel R., Keiser L.W., and Justice G.R. ACORN 9901: a multicenter randomized trial of docetaxel + gemcitabine versus weekly paclitaxel + gemcitabine in patients (pts) with non-small cell lung cancer Proc Am Soc Clin Oncol 21 2002 320a
28. Abstract 1182 Kakolyris S., Tsiafaki X., and Agelidou A. Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer Proc Am Soc Clin Oncol 21 2002 296a
29. Georgoulias V., Papadakis E., Alexopoulos A., Tsiafaki X., Rapti A., and Vesiemes M. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial Lancet 357 2001 1478 1484
30. Abstract 7071 Rigas J.R., Carey M., and Cole B. Multicenter web-based phase III study to test the survival equivalence of nonplatinum-based (NPB) vs platinum-based (PB) therapy for advancednon-small cell lung cancer (NSCLC): the Dartmouth NPB Chemotherapy Trial (D0112) Proc Soc Am Oncol 23 2004 631
31. Abstract 0-218 Mezger J., Pilz L.R., Koschel G., Schoff K., Hruske D., and Manegold C. Single-agent gemcitabine (G) and docetaxel (D) given sequentially every 3 weeks in advanced NSCLC: final results and quality of life assessment of a randomized phase II study show effective treatment Lung Cancer 41 suppl 2 2003 S64
32. Abstract 7056 Hesketh P.J., Chansky K., and Lau D.H. Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age >70, or with performance status (PS) 2: a SWOG phase II trial (50027) Proc Soc Am Oncol 23 2004 627
33. Abstract 2623 Douillard J.-Y., Gervais R., and Dabouis G. A sequential two-line strategy chemotherapy for stage IV non-small cell lung cancer (NSCLC): docetaxel (TXT) + cisplatin (CDDP) vs vinorelbine (V) + CDDP followed by crossover at progression. Final results of a randomized phase II study Proc Am Soc Clin Oncol 22 2003 652
34. (Suppl) Manegold C., Gervais R., and Aigner K. Pemetrexed vs docetaxel: a phase III study in patients with advanced non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy Abstract 57 Eur J Cancer 1 2003 S22 s2
35. Rosell R., Fossella F., and Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer Lung Cancer 38 2002 S43 S49
36. Abstract 7107 Fanucchi M.P., Belt R.J., and Fossella F.V. Phase (ph) II study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): preliminary results Proc Am Soc Clin Oncol 23 2004 640
37. Abstract 7342 Williams C.C., Haura E.B., and Antonia S.J. Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced non-small cell lung cancer (ANSCLC) Proc Am Soc Clin Oncol 23 2004 698